South Korean dermatology biotech Skinmed has received approval from the Ministry of Food and Drug Safety (MFDS) for its Phase 1 clinical trial of SMD-101 (aripotide), a first-in-class peptide-based drug candidate designed to replace botulinum toxin. The development signals a potential shift in the aesthetic injectables market, offering overseas buyers and distributors a novel, faster-acting, and reversible alternative to traditional neurotoxin formulations.
Clinical trial details
The Phase 1 study will be conducted at Chungnam National University Hospital with 54 healthy adult volunteers. It aims to evaluate the pharmacokinetics, safety, and tolerability of SMD-101, while also assessing its local muscle relaxation efficacy through the pharmacodynamic biomarker CMAP. The trial design reflects a rigorous approach to validating the drug's performance in humans.
Mechanism and competitive edge
SMD-101 is being developed as the first peptide-based alternative to botulinum toxin. Unlike conventional botulinum toxin products that must penetrate cells directly, aripotide binds directly to acetylcholine receptors on nerve terminals. This unique mechanism enables faster onset of action, and preclinical data have demonstrated superior safety and reversible recovery profiles compared to existing neurotoxin products.
Regulatory milestone
Skinmed CEO Lee Jeung-hoon stated, "This IND approval is official recognition from the national regulatory authority of our accumulated peptide drug development capabilities. Through thorough and transparent clinical trials, we will offer a safer and more effective therapeutic alternative for patients and the market that have been dissatisfied with the limitations of existing botulinum toxin treatments."
What buyers should watch
For aesthetic clinics and distributors evaluating next-generation injectables, SMD-101's peptide-based mechanism could address key pain points such as slow onset and irreversible effects associated with current botulinum toxin products. Importers should monitor Phase 1 results for safety and efficacy data, as well as Skinmed's subsequent regulatory strategy for global markets including the US and Europe.
Source: Read the original report | Published: June 08, 2026